{
  "_originalData": {
    "identity": {
      "bacteriumName": "Stenotrophomonas maltophilia",
      "lastUpdated": "2025-05-06",
      "clsiCategory": "Stenotrophomonas maltophilia",
      "classification": {
        "gramStain": "Gram negative",
        "morphology": "bacilli",
        "respiration": "",
        "notes": []
      },
      "strainDetails": [],
      "biochemicalTests": "Gram-negative rod, oxidase â€“, catalase +, motile, non-lactose fermenter, oxidizes maltose strongly, DNase +, lysine decarboxylase +."
    },
    "clinicalProfile": {
      "summary": "Stenotrophomonas maltophilia causes pneumonia, bacteremia, and other infections. Immunocompromised and/or debilitated patients are predisposed. It can also be an etiology of acute exacerbations in patients with cystic fibrosis.",
      "highRiskPopulations": [
        "Immunocompromised and/or debilitated patients",
        "Patients with cystic fibrosis"
      ],
      "prognosisNotes": [
        "There is no standard of care regimen. IDSA guidance suggests using combination therapy to prevent the emergence of resistance."
      ]
    },
    "resistanceProfile": {
      "intrinsicResistance": [
        {
          "drugOrClass": "beta-lactams (penicillins, cephalosporins, aztreonam, and carbapenems)",
          "notes": "due to chromosomal zinc-dependent metallo-beta-lactamase, production of ESBLs, and OXA-type beta-lactamase."
        }
      ],
      "inVitroSusceptibility": {
        "data": "From 1,839 clinical isolates: Trimethoprim-sulfamethoxazole 95.4%, Levofloxacin 78.0%, Minocycline 99.5%, Ceftazidime 20.9% (not recommended as monotherapy).",
        "newer_agents": "Omadacycline, Eravacycline, and Cefiderocol are active in vitro but have limited or no clinical data."
      }
    },
    "treatment": {
      "generalNotes": [
        "Therapy is almost always in response to a positive culture and is guided by in vitro susceptibility results."
      ],
      "regimens": [
        {
          "context": {
            "type": "Directed",
            "condition": "Mild infections and polymicrobial infections where S. maltophilia's role is unclear"
          },
          "recommendations": [
            {
              "preference": "Primary",
              "drugs": [
                {
                  "drugName": "TMP-SMX",
                  "dose": "10-15 mg/kg/day",
                  "route": "IV/po",
                  "frequency": "q8h or q12h",
                  "comments": "based on TMP component"
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "Uncomplicated cystitis"
          },
          "recommendations": [
            {
              "preference": "Primary",
              "drugs": [
                {
                  "drugName": "TMP-SMX",
                  "dose": "160/800 mg",
                  "route": "po",
                  "frequency": "q12h"
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "Moderately severe or severe infections"
          },
          "recommendations": [
            {
              "preference": "Alternative",
              "strategy": "Concurrent",
              "notes": [
                "Combination therapy with two of the following: TMP-SMX (10-15 mg/kg/d IV/po divided q8h or q12h), Levofloxacin (750 mg IV/po q24h), Minocycline (200 mg IV/po q12h), or Cefiderocol (2 g IV q8h infused over 3 hours)."
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Concurrent",
              "drugs": [
                {
                  "drugName": "Ceftazidime-avibactam",
                  "dose": "2.5 gm",
                  "route": "IV",
                  "frequency": "q8h",
                  "comments": "infused over 3h"
                },
                {
                  "drugName": "Aztreonam",
                  "dose": "2 gm",
                  "route": "IV",
                  "frequency": "q8h",
                  "comments": "infused over 2h"
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "Mild infections and polymicrobial infections where S. maltophilia's role is unclear"
          },
          "recommendations": [
            {
              "preference": "Alternative",
              "strategy": "Monotherapy",
              "notes": [
                "Monotherapy with TMP-SMX, Levofloxacin, Minocycline, or Cefiderocol."
              ]
            }
          ]
        }
      ]
    },
    "additionalInformation": {
      "antimicrobialStewardship": [
        "Depending on the severity of illness, source control, in vitro susceptibility, and clinical response, de-escalation to oral TMP-SMX or Minocycline can be considered after initial combination therapy."
      ],
      "drugSpecificPearls": [
        {
          "drugName": "Levofloxacin",
          "pearl": "Observational evidence suggests levofloxacin is a reasonable alternative to TMP-SMX for bloodstream and lower respiratory tract infections."
        },
        {
          "drugName": "Cefiderocol",
          "pearl": "FDA-approved for complicated UTI with limited alternatives. In a trial, mortality was 24.8% for cefiderocol vs 18.4% for BAT (not statistically significant). It is active in vitro and in animal models against both TMP/SMX susceptible and resistant strains."
        },
        {
          "drugName": "Polymyxins",
          "pearl": "Most strains are susceptible to polymyxins in vitro, but they are rarely used due to toxicity. Polymyxin B should not be used for UTIs, while Colistin can be reserved for UTIs."
        },
        {
          "drugName": "Tigecycline",
          "pearl": "The FDA cites a higher risk of death with tigecycline compared to other antibacterials and recommends its use only when alternative therapy is not suitable."
        }
      ]
    }
  },
  "_metadata": {
    "originalKeys": [
      "identity",
      "clinicalProfile",
      "resistanceProfile",
      "treatment",
      "additionalInformation"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.354Z",
    "sourceFormat": "modern"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "identity.bacteriumName"
      ],
      "value": "Stenotrophomonas maltophilia"
    },
    "aliases": {
      "sources": [
        "identity.aliases",
        "aliases"
      ],
      "value": []
    },
    "lastUpdated": {
      "sources": [
        "identity.lastUpdated"
      ],
      "value": "2025-05-06"
    },
    "classification": {
      "sources": [
        "identity.classification"
      ],
      "value": {
        "gramStain": "Gram negative",
        "morphology": "bacilli",
        "respiration": "",
        "notes": []
      }
    }
  },
  "clinicalInformation": {
    "sources": [
      "clinicalProfile"
    ],
    "value": {
      "summary": "Stenotrophomonas maltophilia causes pneumonia, bacteremia, and other infections. Immunocompromised and/or debilitated patients are predisposed. It can also be an etiology of acute exacerbations in patients with cystic fibrosis.",
      "highRiskPopulations": [
        "Immunocompromised and/or debilitated patients",
        "Patients with cystic fibrosis"
      ],
      "prognosisNotes": [
        "There is no standard of care regimen. IDSA guidance suggests using combination therapy to prevent the emergence of resistance."
      ]
    }
  },
  "resistanceInformation": {
    "sources": [
      "resistanceProfile"
    ],
    "value": {
      "intrinsicResistance": [
        {
          "drugOrClass": "beta-lactams (penicillins, cephalosporins, aztreonam, and carbapenems)",
          "notes": "due to chromosomal zinc-dependent metallo-beta-lactamase, production of ESBLs, and OXA-type beta-lactamase."
        }
      ],
      "inVitroSusceptibility": {
        "data": "From 1,839 clinical isolates: Trimethoprim-sulfamethoxazole 95.4%, Levofloxacin 78.0%, Minocycline 99.5%, Ceftazidime 20.9% (not recommended as monotherapy).",
        "newer_agents": "Omadacycline, Eravacycline, and Cefiderocol are active in vitro but have limited or no clinical data."
      }
    }
  },
  "treatmentData": {
    "treatmentData": {
      "_treatmentMetadata": {
        "originalFormat": "modern"
      },
      "standardizedRegimens": []
    }
  },
  "laboratoryData": {
    "sources": [
      "laboratoryProfile",
      "laboratory"
    ],
    "value": {}
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobial_stewardship",
        "antimicrobialStewardship"
      ],
      "value": []
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "object"
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {}
  }
}